Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 265 to 270 of 270 entries
Sorted by: Best Match Show Resources per page
A 16-parts-per-trillion measurement of the antiproton-to-proton charge-mass ratio.

Nature

Borchert MJ, Devlin JA, Erlewein SR, Fleck M, Harrington JA, Higuchi T, Latacz BM, Voelksen F, Wursten EJ, Abbass F, Bohman MA, Mooser AH, Popper D, Wiesinger M, Will C, Blaum K, Matsuda Y, Ospelkaus C, Quint W, Walz J, Yamazaki Y, Smorra C, Ulmer S.
PMID: 34987217
Nature. 2022 Jan;601(7891):53-57. doi: 10.1038/s41586-021-04203-w. Epub 2022 Jan 05.

The standard model of particle physics is both incredibly successful and glaringly incomplete. Among the questions left open is the striking imbalance of matter and antimatter in the observable universe

Cite
Borchert MJ, Devlin JA, Erlewein SR, et al. A 16-parts-per-trillion measurement of the antiproton-to-proton charge-mass ratio. Nature. 2022;601(7891):53-57doi: 10.1038/s41586-021-04203-w.
Borchert, M. J., Devlin, J. A., Erlewein, S. R., Fleck, M., Harrington, J. A., Higuchi, T., Latacz, B. M., Voelksen, F., Wursten, E. J., Abbass, F., Bohman, M. A., Mooser, A. H., Popper, D., Wiesinger, M., Will, C., Blaum, K., Matsuda, Y., Ospelkaus, C., Quint, W., Walz, J., Yamazaki, Y., Smorra, C., & Ulmer, S. (2022). A 16-parts-per-trillion measurement of the antiproton-to-proton charge-mass ratio. Nature, 601(7891), 53-57. https://doi.org/10.1038/s41586-021-04203-w
Borchert, M J, et al. "A 16-parts-per-trillion measurement of the antiproton-to-proton charge-mass ratio." Nature vol. 601,7891 (2022): 53-57. doi: https://doi.org/10.1038/s41586-021-04203-w
Borchert MJ, Devlin JA, Erlewein SR, Fleck M, Harrington JA, Higuchi T, Latacz BM, Voelksen F, Wursten EJ, Abbass F, Bohman MA, Mooser AH, Popper D, Wiesinger M, Will C, Blaum K, Matsuda Y, Ospelkaus C, Quint W, Walz J, Yamazaki Y, Smorra C, Ulmer S. A 16-parts-per-trillion measurement of the antiproton-to-proton charge-mass ratio. Nature. 2022 Jan;601(7891):53-57. doi: 10.1038/s41586-021-04203-w. Epub 2022 Jan 05. PMID: 34987217.
Copy Download .nbib Format: NLM
CPX-351 (Vyxeos.

Clinical case reports

Urbantat RM, Popper V, Menschel E, Pfeilstöcker M, Forjan E, Nader A, Sieghart CR, Keil F, Koller E, Tibubos AN.
PMID: 33936618
Clin Case Rep. 2021 Feb 12;9(4):1933-1936. doi: 10.1002/ccr3.3909. eCollection 2021 Apr.

CPX-351, a promising new agent for patients with treatment-related and secondary acute myeloid leukemia can lead to a severe whole-body rash. Although severe side effects are rare, treatment should be carefully monitored at specialized centers.

Cite
Urbantat RM, Popper V, Menschel E, et al. CPX-351 (Vyxeos. Clin Case Rep. 2021;9(4):1933-1936doi: 10.1002/ccr3.3909.
Urbantat, R. M., Popper, V., Menschel, E., Pfeilstöcker, M., Forjan, E., Nader, A., Sieghart, C. R., Keil, F., Koller, E., & Tibubos, A. N. (2021). CPX-351 (Vyxeos. Clinical case reports, 9(4), 1933-1936. https://doi.org/10.1002/ccr3.3909
Urbantat, Ruth M, et al. "CPX-351 (Vyxeos." Clinical case reports vol. 9,4 (2021): 1933-1936. doi: https://doi.org/10.1002/ccr3.3909
Urbantat RM, Popper V, Menschel E, Pfeilstöcker M, Forjan E, Nader A, Sieghart CR, Keil F, Koller E, Tibubos AN. CPX-351 (Vyxeos. Clin Case Rep. 2021 Feb 12;9(4):1933-1936. doi: 10.1002/ccr3.3909. eCollection 2021 Apr. PMID: 33936618; PMCID: PMC8077323.
Copy Download .nbib Format: NLM
Sympathetic cooling of a trapped proton mediated by an LC circuit.

Nature

Bohman M, Grunhofer V, Smorra C, Wiesinger M, Will C, Borchert MJ, Devlin JA, Erlewein S, Fleck M, Gavranovic S, Harrington J, Latacz B, Mooser A, Popper D, Wursten E, Blaum K, Matsuda Y, Ospelkaus C, Quint W, Walz J, Ulmer S.
PMID: 34433946
Nature. 2021 Aug;596(7873):514-518. doi: 10.1038/s41586-021-03784-w. Epub 2021 Aug 25.

Efficient cooling of trapped charged particles is essential to many fundamental physics experiments

Cite
Bohman M, Grunhofer V, Smorra C, et al. Sympathetic cooling of a trapped proton mediated by an LC circuit. Nature. 2021;596(7873):514-518doi: 10.1038/s41586-021-03784-w.
Bohman, M., Grunhofer, V., Smorra, C., Wiesinger, M., Will, C., Borchert, M. J., Devlin, J. A., Erlewein, S., Fleck, M., Gavranovic, S., Harrington, J., Latacz, B., Mooser, A., Popper, D., Wursten, E., Blaum, K., Matsuda, Y., Ospelkaus, C., Quint, W., Walz, J., Ulmer, S. (2021). Sympathetic cooling of a trapped proton mediated by an LC circuit. Nature, 596(7873), 514-518. https://doi.org/10.1038/s41586-021-03784-w
Bohman, M, et al. "Sympathetic cooling of a trapped proton mediated by an LC circuit." Nature vol. 596,7873 (2021): 514-518. doi: https://doi.org/10.1038/s41586-021-03784-w
Bohman M, Grunhofer V, Smorra C, Wiesinger M, Will C, Borchert MJ, Devlin JA, Erlewein S, Fleck M, Gavranovic S, Harrington J, Latacz B, Mooser A, Popper D, Wursten E, Blaum K, Matsuda Y, Ospelkaus C, Quint W, Walz J, Ulmer S. Sympathetic cooling of a trapped proton mediated by an LC circuit. Nature. 2021 Aug;596(7873):514-518. doi: 10.1038/s41586-021-03784-w. Epub 2021 Aug 25. PMID: 34433946; PMCID: PMC8387233.
Copy Download .nbib Format: NLM
Evaluation of prognostic factors after primary chemoradiotherapy of anal cancer: A multicenter study of the German Cancer Consortium - Radiation Oncology Group (DKTK-ROG).

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Martin D, Schreckenbach T, Ziegler P, Filmann N, Kalinauskaite G, Tinhofer I, Budach V, Gani C, Zips D, Schimek-Jasch T, Schäfer H, Grosu AL, Thomas E, Krause M, Dapper H, Combs S, Hoffmann C, Stuschke M, Walter F, Belka C, Kurth I, Hadiwikarta WW, Baumann M, Rödel C, Fokas E.
PMID: 34999135
Radiother Oncol. 2022 Jan 06; doi: 10.1016/j.radonc.2021.12.050. Epub 2022 Jan 06.

BACKGROUND AND PURPOSE: Prognosis after chemoradiotherapy (CRT) for anal squamous cell carcinoma (ASCC) shows marked differences among patients according to TNM subgroups, however individualized risk assessment tools to better stratify patients for treatment (de-) escalation or intensified follow-up are...

Cite
Martin D, Schreckenbach T, Ziegler P, et al. Evaluation of prognostic factors after primary chemoradiotherapy of anal cancer: A multicenter study of the German Cancer Consortium - Radiation Oncology Group (DKTK-ROG). Radiother Oncol. 2022;doi: 10.1016/j.radonc.2021.12.050.
Martin, D., Schreckenbach, T., Ziegler, P., Filmann, N., Kalinauskaite, G., Tinhofer, I., Budach, V., Gani, C., Zips, D., Schimek-Jasch, T., Schäfer, H., Grosu, A. L., Thomas, E., Krause, M., Dapper, H., Combs, S., Hoffmann, C., Stuschke, M., Walter, F., Belka, C., Kurth, I., Hadiwikarta, W. W., Baumann, M., Rödel, C., & Fokas, E. (2022). Evaluation of prognostic factors after primary chemoradiotherapy of anal cancer: A multicenter study of the German Cancer Consortium - Radiation Oncology Group (DKTK-ROG). Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, . https://doi.org/10.1016/j.radonc.2021.12.050
Martin, D, et al. "Evaluation of prognostic factors after primary chemoradiotherapy of anal cancer: A multicenter study of the German Cancer Consortium - Radiation Oncology Group (DKTK-ROG)." Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology vol. (2022). doi: https://doi.org/10.1016/j.radonc.2021.12.050
Martin D, Schreckenbach T, Ziegler P, Filmann N, Kalinauskaite G, Tinhofer I, Budach V, Gani C, Zips D, Schimek-Jasch T, Schäfer H, Grosu AL, Thomas E, Krause M, Dapper H, Combs S, Hoffmann C, Stuschke M, Walter F, Belka C, Kurth I, Hadiwikarta WW, Baumann M, Rödel C, Fokas E. Evaluation of prognostic factors after primary chemoradiotherapy of anal cancer: A multicenter study of the German Cancer Consortium - Radiation Oncology Group (DKTK-ROG). Radiother Oncol. 2022 Jan 06; doi: 10.1016/j.radonc.2021.12.050. Epub 2022 Jan 06. PMID: 34999135.
Copy Download .nbib Format: NLM
Revacept, an Inhibitor of Platelet Adhesion in Symptomatic Carotid Artery Stenosis: Design and Rationale of a Randomized Phase II Clinical Trial.

TH open : companion journal to thrombosis and haemostasis

Gröschel K, Uphaus T, Loftus I, Poppert H, Diener HC, Zobel J, Münch G.
PMID: 33274312
TH Open. 2020 Nov 30;4(4):e393-e399. doi: 10.1055/s-0040-1721078. eCollection 2020 Oct.

Patients with stroke or transient ischemic attacks (TIAs) and internal carotid artery stenosis harbor an increased risk of recurrent stroke especially within 2 weeks after the first event. In addition, the revascularization procedure itself (carotid endarterectomy [CEA] or carotid...

Cite
Gröschel K, Uphaus T, Loftus I, et al. Revacept, an Inhibitor of Platelet Adhesion in Symptomatic Carotid Artery Stenosis: Design and Rationale of a Randomized Phase II Clinical Trial. TH Open. 2020;4(4):e393-e399doi: 10.1055/s-0040-1721078.
Gröschel, K., Uphaus, T., Loftus, I., Poppert, H., Diener, H. C., Zobel, J., & Münch, G. (2020). Revacept, an Inhibitor of Platelet Adhesion in Symptomatic Carotid Artery Stenosis: Design and Rationale of a Randomized Phase II Clinical Trial. TH open : companion journal to thrombosis and haemostasis, 4(4), e393-e399. https://doi.org/10.1055/s-0040-1721078
Gröschel, Klaus, et al. "Revacept, an Inhibitor of Platelet Adhesion in Symptomatic Carotid Artery Stenosis: Design and Rationale of a Randomized Phase II Clinical Trial." TH open : companion journal to thrombosis and haemostasis vol. 4,4 (2020): e393-e399. doi: https://doi.org/10.1055/s-0040-1721078
Gröschel K, Uphaus T, Loftus I, Poppert H, Diener HC, Zobel J, Münch G. Revacept, an Inhibitor of Platelet Adhesion in Symptomatic Carotid Artery Stenosis: Design and Rationale of a Randomized Phase II Clinical Trial. TH Open. 2020 Nov 30;4(4):e393-e399. doi: 10.1055/s-0040-1721078. eCollection 2020 Oct. PMID: 33274312; PMCID: PMC7704244.
Copy Download .nbib Format: NLM
Adaptation and Preliminary Testing of an Intervention to Reduce Stigma among Individuals Living with HIV in the Deep South.

Social work in public health

Reif S, Rao D, Wilson E, Beckwith N, Frey S, Cooper H, Ward D, Belden M.
PMID: 34464238
Soc Work Public Health. 2022 Jan 02;37(1):1-13. doi: 10.1080/19371918.2021.1965937. Epub 2021 Aug 31.

HIV-related stigma has been implicated as a contributor to the disproportionate impact of HIV in the US Deep South. However, effective interventions aimed at reducing HIV-related stigma are limited in the region. This study adapted and piloted an HIV-related...

Cite
Reif S, Rao D, Wilson E, et al. Adaptation and Preliminary Testing of an Intervention to Reduce Stigma among Individuals Living with HIV in the Deep South. Soc Work Public Health. 2021;37(1):1-13doi: 10.1080/19371918.2021.1965937.
Reif, S., Rao, D., Wilson, E., Beckwith, N., Frey, S., Cooper, H., Ward, D., & Belden, M. (2022). Adaptation and Preliminary Testing of an Intervention to Reduce Stigma among Individuals Living with HIV in the Deep South. Social work in public health, 37(1), 1-13. https://doi.org/10.1080/19371918.2021.1965937
Reif, Susan, et al. "Adaptation and Preliminary Testing of an Intervention to Reduce Stigma among Individuals Living with HIV in the Deep South." Social work in public health vol. 37,1 (2022): 1-13. doi: https://doi.org/10.1080/19371918.2021.1965937
Reif S, Rao D, Wilson E, Beckwith N, Frey S, Cooper H, Ward D, Belden M. Adaptation and Preliminary Testing of an Intervention to Reduce Stigma among Individuals Living with HIV in the Deep South. Soc Work Public Health. 2022 Jan 02;37(1):1-13. doi: 10.1080/19371918.2021.1965937. Epub 2021 Aug 31. PMID: 34464238.
Copy Download .nbib Format: NLM
Showing 265 to 270 of 270 entries